Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Has been correlated with btc, bought a large block at the dip at 28 and some more yesterday at 36, looking for more than a triple, this has had over 200m volume many days, only a matter of time. My Argo, reloaded at .96 doing amazing, also have BTCWF which has been a little out of sync with btc recently, pays to diversify!
ARB Over 29% in London, hope that carries over to the American ticker!
Up 26% and rising in London
https://www.londonstockexchange.com/stock/ARB/argo-blockchain-plc/company-page
Not worried about authorized shares. This is OTC land. The most that I have seen is Biel which has 25 billion authorized shares and is at almost the same price as CCTL, so our stock here is actually worth about 6x more so it would be like 1.8 cents compared to Biel which I also have!
I think that your instinct to return back now is correct. You are definitely good luck for the stock!
E*TRADE showing .0034 close, not bad considering bumpiness of btc today. The good news is that it pops or drops much more than what btc is doing at the minute. My take is that when btc touches 40k this should be at a penny, if not then it would be a bust. We’ll see the week is just starting!
They released a or from Syracuse many months ago about Pritumumab blocking COVID replication in cells. Would be great if we get more specific information. Now is the time for Sean Carrick with 10 million shares to get to work. I am not holding my breath, I’ve moved to some btc mining stocks which I hope will have a great week, but these shares are parked away, who would sell at 6 cents???
Seems like a sure thing but $ARBKF tracked bitcoin perfectly today and Coin Citadel didn’t jump at end of day but I expect it will. I have both, roughly equal cash in each.
I hope Sean Carrick and team have a plan to do frequent news driops, except for financials we haven’t heard anything about the science for a while. Would like a real paper from Syracuse...that would get me excited!
If I buy 10k at 0.09 will that hold or just be foolish?
Exactly right! The crap bios have been on insane runs, we actually have a product and clinical trials. Disadvantage is OTC, Fidelity and maybe others don’t allow trades. E*TRADE is always awesome though. A 500% run to only .25 would make up for the lost opportunity cost of holding and accumulating the last quarter of 2020.
I think patience will pay off, let’s see .10’s this week and then big gains on news.
Hopefully today’s the day we hit 10 cents again, which is the maximum price on the new stock offering, that would bring in lots of newbies accumulating shares. When that happens I don’t see us going back.
Completely novel mechanism of action for blocking COVID from entering cells, need more specifics on that, preferable a published paper from Syracuse. Also completely novel mechanism of action for brain cancer treatment. Don’t think it will take off until January, it may be taken a little bit lower before end of year, so I personally think loading in 2021 is a go.
So much potential!
https://www.donjoyperformance.com/catalogsearch/result?q=Actipatch
Not bad at all! Here’s a rundown of what had to happen to make the Donjoy EME back and knee wrap possible
Engineers need to CAD model the product Including a cool looking integration of the actipatch “halo”
Designers need to prototype, cut, sew, and test that it fits as cool as it looks
Product needs to be manufactured, packaged, and distributed to warehouses so that online order can be fulfilled quickly
Coders need to update website, photographers need to get high quality image on knee and back model
Writer needs to write short blurb
Link to online shopping cart created
All in all a lot of effort! Now all sales team has to do is market and sell, if all of us shareholders 100 or 200 whatever spent the $70 and got one or $140 and got both from donjoy then that would be almost 300k in revenue
A small price for us to pay to see revenues, were an older group though so we need to get younger relatives to post to tic toc, Instagram etc to get out the word, The marketing team should be doing that but maybe they’re also too old
We’ve had plenty of time to accumulate, no need to be at this price anymore. Needs more frequent and specific PRs, definitely has not performed well at all like We thought it would!
Pritumumab the first therapeutic antibody for glioma patients
249 brain cancer patients in Japan treated with Pritumumab with no additional serious adverse effects (except having brain cancer)
What other OTC (QB) has a safe monoclonal antibody that has been through such extensive human testing at this price?
Here’s hoping one day that the world has discovered the value here!
https://content.iospress.com/articles/human-antibodies/hab326
Gradually built up my position. Was able to buy for a discount over past few weeks, now with some good PRs, hopefully COVID will move this stock. Need More information from Alison Patteson lab at Syracuse about the specifics of the study so that it can build more buzz, a published paper would be great. Also an update from Manhattan BioSolutions. Hoping for a big next two months. On a side note, Sean Carrick and management got compensated at .10 a share so I expect they would like to have their full salary paid at .1 a share, that should bode well for a regular supply of PRs
Are we still in accumulation? I’m not knowledgeable on MM but are they trying to keep it at an attractive price for new buyers? IMO 6 cents looks more enticing especially when it hit .25 in April it on COVID excitement. chance for 400% pop here but we want $1 or more..after the pop and when Nbio is a regular in the breakout boards!
Is it go time? Waiting for $1 when things get cooking!
https://www.businesswire.com/news/home/20201021005674/en/
Cyclo Therapeutics Phase 3 Pivotal Program Can Begin Enrollment Per US FDA
Cyclo Therapeutics will now proceed in the US with its Phase 3 clinical trial of Trappsol® Cyclo™ for treatment of Niemann-Pick Disease Type C
October 21, 2020 10:53 AM Eastern Daylight Time
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of Neurodegenerative Diseases, including their lead candidate (Trappsol® Cyclo™) in the treatment of Niemann-Pick Disease Type C (NPC) today announced that the company received notification from the US FDA that enrollment can proceed for its Phase 3 global pivotal clinical trial, “A Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ (Hydroxypropyl-ß-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann-Pick Disease Type C1”.
“We are grateful to the FDA for the positive feedback on our Phase 3 pivotal study design”
Tweet this
“We are very pleased to receive the FDA’s notification that we can proceed with the Phase 3 clinical trial. This announcement signifies the most significant milestone for our company but also for the patients, families and caregivers in the NPC Community as well,” said company CEO N Scott Fine. “We will continue to collaborate with the NPC community as we drive this study forward towards market authorization as rapidly as possible.”
“Through our Fast Track designation, we were able to engage in ongoing collaboration with the US FDA which has enabled us to proceed quickly in the US,” said company Chief Regulatory Officer Michael Lisjak. “We will continue to execute on our parallel efforts with the EMA and other regulatory bodies to achieve a similar outcome on our Phase 3 pivotal program outside the US.”
“We are grateful to the FDA for the positive feedback on our Phase 3 pivotal study design,” said company Chief Scientific Officer and Senior Vice President for Medical Affairs, Sharon Hrynkow, PhD. “We are excited to launch our first clinical sites in the US in the near term, with confidence that the European sites and other global sites will follow in short order.”
Niemann-Pick Disease Type C is a rare genetic disease affecting 1 in 100,000 live births globally. NPC affects every cell in the body due to a defect in the NPC1 protein which is responsible for cholesterol processing in the cell. NPC causes symptoms in the brain, liver, spleen, lung and other organs and often leads to premature death. There are no approved drug therapies for NPC in the United States and only one approved therapy in Europe.
About Cyclo Therapeutics:
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (ClinicalTrials.gov NCT02939547, NCT02912793 and NCT03893071). The company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company’s website: www.cyclotherapeutics.com
Safe Harbor Statement:
This press release contains “forward-looking statements” about the company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company’s future performance include the company’s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company’s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company’s filings with the Securities and Exchange Commission, including, but not limited to, the company’s reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
Contacts
Investor/Media Contact:
Jeffrey L. Tate, Ph.D. COO
Cyclo Therapeutics, Inc.
jeff@cyclodex.com
+1 (386) 418-8060
Great news yesterday that Pritumumab blocks COVID entry into cells but no specifics yet, in terms of a published results. I hope that it can fly to .25 on news and that insiders will keep holding so that it can maintain price but it looks like it’s a couple months off from now
Big news today, wait till it picks up more steam and more scientific details are put out by the Patterson lab:
http://dailyorange.com/2020/10/professor-researches-antibody-possible-treatment-covid-19/
“Evidence has been found that the antibody does block the uptake to viral particles,” Patteson said.
Let’s hope soon that we can make some serious money, everyone loaded?
Pritumumab information from 2018 paper, worth repeating now:
“Pritumumab is a natural human monoclonal antibody developed from a B lymphocyte isolated from a regional draining lymph node of a patient with cervical carcinoma. The antibody binds ecto-domain vimentin on the surface of cancer cells. Pritumumab was originally tested in clinical trials with brain cancer patients in Japan where it demonstrated therapeutic benefit. It was reported to be a safe and effective therapy for brain cancer patients at doses 5-10 fold less than currently approved antibodies. “
Source: https://pubmed.ncbi.nlm.nih.gov/29036806/
Waiting for Syracuse U. to provide data so that the President can get 100% safe humanized monoclonal antibody
Pritumumab well it couldn’t hurt at least!
Looks good, still alive and kicking!
https://www.accesswire.com/608585/Nascent-Biotech-Continues-to-Reduce-Liabilities-by-Over-20-Million-Dollars
Buyers showed up today that tells me that there are more people interested in rolling the dice here Before Syracuse news comes out. As long as execs hold their shares and don’t sell to pay this months electricity in the office, the buying pressure should lift us.
The stock my opinion trades independent of app. This is normal trading for TTCM finding a new channel, I can’t speculate on what that is.
As has been said many times here if you are a disciplined trader and waited patiently bought at .003’s to 0.005’s and waited for 1.9, then in the last year good traders better than me could have made their 400% and now could buy in or wait a little lower for the repeat even if it takes a few months. That has been the pattern of this stock, so we will see. I don’t think this yearly pattern has anything to do with DLM, and I still have some 0013’s from spring 2019, so obviously I couldn’t time the top but waiting to see this through.
Will NBIO open at 0.1525 tomorrow? I mean that’s barely a 100% gain and nothing unusual in OTC. We deserve it right?
Agreed, following the trend of increase in volume and share price on PR. Now we just need consistent retail buying. Nbio is a great ticker symbol too, NASDAQ caliber if ibio could run 4000% then why can’t Nbio?
The fact is we don’t know. I can’t blame anyone for losing interest but I think most buyers here, myself included will wait and see what happens over the next few months. I think this may even be one to have to wait out for a big move over the course of a year. I could be wrong but it will take some time to get more liquidity here. Maybe tomorrow news though?
Excellent find! Thanks for posting it, she also says in the paper;
“With SARS-CoV, vimentin binds the viral spike protein and enhances its delivery to the receptor angiotensin-converting enzyme 2.[120] SARS-CoV also upregulates cytoplasmic vimentin by the TGF-ß pathway to promote a fibrotic response in lung cells,[118] “
Last week I was busy accumulating either boom or bust here, hope that it is not a pump and dump, Nbio has been around for a long time. Granted no I would not bet the farm here but if Patterson news from Syracuse comes out positive then we should see a big turnaround, just my observation that market makers let it run on PR days. Also every ticker with the name bio in it is valuable in and of itself. GLTA!
Added another 50+ k here, I know not much but now have 200k iGen. This is a good start to the week for OTCs. Only Monday so hope to see iGen keep it up this week, good price point to accumulate. Will look for 50m volume later this week to push higher.
Getting closer. 750k in funding from private investor announced for moving brain cancer study along. They have gone above and beyond to keep costs low and not take any loans.
data on COVID coming from Boris Shor at Manhattan BioSolutions and Syracuse University.
Brain cancer study:
SAN DIEGO, CA / ACCESSWIRE / August 24, 2020 / Nascent Biotech, Inc (OTCQB:NBIO) announced today that it is closing on a direct private placement with aggregate proceeds of $740,000.
The proceeds allow the Company to complete the required testing for removing the partial clinical trial hold, imposed by the FDA, and will permit the company to begin the Phase I clinical trials on brain cancer.
Sean Carrick, CEO of Nascent commented, "The financing has come from private individual investors and we are pleased by the interest in this round. We chose to accept strategic money knowing equity funding will prove to be more beneficial to the Company than debt financing."
About Nascent Biotech, Inc.:
Nascent Biotech, Inc. is a clinical-stage biotech company pioneering the development of monoclonal antibodies (mAbs) for the treatment of incurable cancers such as brain and pancreas, as well as hard-to-treat cancers such as colon and lung. Nascent is also employing its mAbs as part of treatments for dangerous viral infections, such as COVID-19. Collectively, cancers and viral infections afflict and kill tens of millions worldwide each year. Nascent's products are not commercially available. Our lead candidate, Pritumumab (PTB), is a fully human mAb that will commence study in an FDA-approved Phase I clinical trial later this year for the treatment of primary and metastatic brain cancer, including glioblastoma and malignant astrocytoma. Development of PTB as a potential treatment for COVID-19 has been initiated. For more information, visit www.nascenbiotech.com.
@JustGoDeep, great points. All my Biel is in my IRA, which I can’t touch for a while so next week I will load up some at these prices in my trading account. With your calculations $2000 could be $200,000. Even if this hits single penny land even many months from now, the volume and demand for shares will be enormous. May even be billion share volume?
Great find! 250k in sales to schools and much more to come. How many other OTC companies actually have revenue! Only the best $GAXY
This is with Manhattan BioSolutions, they have a vaccine contract with them.
The Syracuse University one is coming too.
So I think we take another run at .14 soon, hopefully we can get millions in volume and new buyers in!